4.7 Review

The controversial links among calorie restriction, SIRT1, and resveratrol

期刊

FREE RADICAL BIOLOGY AND MEDICINE
卷 51, 期 2, 页码 250-256

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.freeradbiomed.2011.04.034

关键词

Calorie restriction; SIRT1; Resveratrol; Deacetylase; Life span

向作者/读者索取更多资源

It has been widely known that slow metabolism induced by calorie restriction (CR) can extend the life span of model organisms though the underlying mechanism remains poorly understood. Accumulated evidence suggests that SIRT1 may be actively involved in CR-induced signaling pathways. As a putative activator of SIRT1, resveratrol, known for the French paradox, can partially mimic the physiological effects of CR. While the deacetylase activity of SIRT1 is important for the beneficial effects of resveratrol, resveratrol-induced SIRT1 activation has recently been challenged by the observations that resveratrol could not induce SIRT1-mediated deacetylation of native substrates in vitro. To resolve the discrepancy of resveratrol-induced activation of SIRT1 deacetylase activity between the in vitro and in vivo assays, a model of indirect SIRT1 activation by resveratrol is proposed. In this review, we will discuss the emerging roles of SIRT1 and resveratrol in CR and focus on debate over the links between SIRT1 and resveratrol. (C) 2011 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biotechnology & Applied Microbiology

Biofabricated macrophage and fibroblast membranes synergistically promote skin wound healing

Dongqing Wang, Heying Chen, Li Lei, Jun Chen, Jimin Gao, Jiahe Liu, Qianyin Li, Yajun Xie, Yi Hu, Yilu Ni

Summary: Effective skin wound healing involves anti-inflammation, fibrosis, matrix reconstruction, and angiogenesis. This study aimed to integrate macrophage-mediated anti-inflammation and fibroblast-assisted matrix reconstruction to enhance wound healing. The results showed that M2 macrophage cytomembranes promoted wound closure, and the addition of fibroblast membranes contributed to better matrix reconstruction and angiogenesis.

BIOENGINEERING & TRANSLATIONAL MEDICINE (2022)

Article Oncology

Gliosarcoma: The Distinct Genomic Alterations Identified by Comprehensive Analysis of Copy Number Variations

Chuan-dong Cheng, Cheng Chen, Li Wang, Yong-fei Dong, Yang Yang, Yi-nan Chen, Wan-xiang Niu, Wen-chao Wang, Qing-song Liu, Chao-shi Niu

Summary: This study comprehensively analyzed DNA copy number variations (CNV) in glioblastoma (GBM) and gliosarcoma (GSM), revealing both shared and distinct CNV patterns between the two tumors. Pathway analysis of genes with CNV showed similar mechanisms of tumor development in GBM and GSM, but also identified disparate CNV patterns in certain genes unique to GSM.

ANALYTICAL CELLULAR PATHOLOGY (2022)

Article Pharmacology & Pharmacy

PEG-Bottlebrush Stabilizer-Based Worm-like Nanocrystal Micelles with Long-Circulating and Controlled Release for Delivery of a BCR-ABL Inhibitor against Chronic Myeloid Leukemia (CML)

Huamin Liang, Fengming Zou, Liyi Fu, Qingwang Liu, Beilei Wang, Xiaofei Liang, Jing Liu, Qingsong Liu

Summary: Drug nanocrystals, a common drug delivery system, have the potential to enhance the delivery of poorly water-soluble drugs. However, their rapid clearance and uncontrolled drug release limit their effectiveness. In this study, an amphiphilic co-polymer was synthesized as a stabilizer to fabricate high-drug-loading nanocrystal micelles. These micelles exhibited small size, high drug loading, and controlled release in vitro, as well as long circulation and high drug accumulation in vivo. This research provides new possibilities for the development of more efficient nanocrystal-based injection formulations and the potential clinical application of a CML candidate drug.

PHARMACEUTICS (2022)

Article Engineering, Biomedical

Mitochondrial temperature-responsive drug delivery reverses drug resistance in lung cancer

Lifo Ruan, Jun Chen, Chuanchao Du, Huiru Lu, Jiayu Zhang, Xiaomeng Cai, Rui Dou, Wenchu Lin, Zhifang Chai, Guangjun Nie, Yi Hu

Summary: The use of mitochondrial temperature-responsive drug delivery system can prevent drug efflux, facilitate drug accumulation and mitochondrial targeting in drug-resistant tumors. This technology enhances drug toxicity and reverses drug resistance, representing a significant advancement in combating cancer drug resistance.

BIOACTIVE MATERIALS (2022)

Article Chemistry, Multidisciplinary

Repurposing of the FGFR inhibitor AZD4547 as a potent inhibitor of necroptosis by selectively targeting RIPK1

Zuo-wei Wang, Feng-ming Zou, Ao-li Wang, Jing Yang, Rui Jin, Bei-lei Wang, Li-juan Shen, Shuang Qi, Juan Liu, Jing Liu, Wen-chao Wang, Qing-song Liu

Summary: In this study, the researchers discovered that AZD4547, a previously reported FGFR inhibitor, can interfere with Necroptosis by directly targeting RIPK1 kinase. They found that AZD4547 blocked RIPK1-dependent Necroptosis in both human and mouse cell models and rescued animals from TNF-induced lethal shock and inflammatory responses.

ACTA PHARMACOLOGICA SINICA (2023)

Article Chemistry, Analytical

Chemical transformation and cytotoxicity of iron oxide nanoparticles (IONPs) accumulated in mitochondria

Lifo Ruan, Haijing Li, Jiayu Zhang, Mengxue Zhou, Hui Huang, Juncai Dong, Jinxia Li, Feng Zhao, Zhonghua Wu, Jun Chen, Zhifang Chai, Yi Hu

Summary: Iron oxide nanoparticles (IONPs) are widely used in biomedical research, but their subcellular transformation and biological effects are not well understood. In this study, we prepared three types of IONPs, including those targeting mitochondria (IONP-TPP) and lysosomes (IONP-APM), and a control group with no specific target (IONP). Results showed that mitochondria-targeted IONP-TPP induced significant cytotoxicity and mitochondrial membrane depolarization in MCF-7 cells. X-ray absorption spectroscopy (XAS) analysis revealed remarkable edge defects and oxidation of IONP-TPP inside the cell. These findings highlight the potential chemical transformation of IONPs at mitochondria and the vulnerability of mitochondria to IONP accumulation.

TALANTA (2023)

Article Chemistry, Multidisciplinary

Ultrasensitive Small-Molecule Fluorescent Thermometer Reveals Hot Mitochondria in Surgically Resected Human Tumors

Qing Zhu, Yue Sun, Manlin Fu, Mianli Bian, Xiaomei Zhu, Kai Wang, Haoxing Geng, Wei Zeng, Wei Shen, Yi Hu

Summary: The study indicates that mitochondrial temperature in cancer cells may be higher than in normal cells, providing critical evidence for reevaluating cancer metabolism. By using the specially designed near-infrared probe MTN, the fluctuations of mitochondrial temperature in cancer cells can be monitored.

ACS SENSORS (2022)

Article Pharmacology & Pharmacy

Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy

Chen Hua, Lijuan Shena, Fengming Zoua, Yun Wua, Beilei Wanga, Aoli Wanga, Chao Wud, Li Wanga, Jing Liua, Wenchao Wanga, Qingsong Liua

Summary: The study reveals a novel resistance mechanism for CDK9 inhibitors mediated by the L156F mutation, which disrupts the binding of inhibitors with CDK9 due to steric hindrance, and affects the thermal stability and catalytic activity of CDK9 protein. A new compound IHMT-CDK9-36 showed potent inhibition activity for both CDK9 WT and L156F mutant, providing a new chemical scaffold for the future development of CDK9 inhibitors.

ACTA PHARMACEUTICA SINICA B (2023)

Article Chemistry, Medicinal

Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor

Qianmao Liang, Beilei Wang, Fengming Zou, Gongrui Guo, Wenliang Wang, Wei Wang, Qingwang Liu, Lijuan Shen, Chen Hu, Wenchao Wang, Aoli Wang, Tao Huang, Yuying He, Ruixiang Xia, Jian Ge, Jing Liu, Qingsong Liu

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Pharmacology & Pharmacy

Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment

Aoli Wang, Juan Liu, Xixiang Li, Fengming Zou, Ziping Qi, Shuang Qi, Qingwang Liu, Zuowei Wang, Jiangyan Cao, Zongru Jiang, Beilei Wang, Juan Ge, Li Wang, Wenchao Wang, Jing Liu, Qingsong Liu

Summary: In this study, a highly potent pan-RAF inhibitor, IHMT-RAF-128, was developed, which demonstrated strong anti-tumor efficacy against cancer cells harboring RAF or RAS mutations, especially the KRAS-G12C secondary mutations resistant to AMG510. IHMT-RAF-128 also exhibited excellent pharmacokinetic profile and dose-dependent anti-tumor efficacy in xenograft mouse tumor models without obvious toxicities. These findings support further investigation of IHMT-RAF-128 as a potential clinical drug candidate for cancer patients with RAF or RAS mutations.

EUROPEAN JOURNAL OF PHARMACOLOGY (2023)

Article Biochemistry & Molecular Biology

Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitus

Junjie Wang, Ziping Qi, Yun Wu, Aoli Wang, Qingwang Liu, Fengming Zou, Beilei Wang, Shuang Qi, Jiangyan Cao, Chen Hu, Chenliang Shi, Qianmao Liang, Li Wang, Jing Liu, Wenchao Wang, Qingsong Liu

Summary: Insulin-producing pancreatic beta cell death is the fundamental cause of type 1 diabetes (T1D) and a contributing factor to type 2 diabetes (T2D). MST1 contributes to the progression of diabetes mellitus through apoptosis induction and acceleration of pancreatic beta cell dysfunction. Activation of AMPK has been suggested as a treatment option for metabolic diseases, making the pharmacological inhibition of MST1 and activation of AMPK simultaneously a promising approach for diabetes therapy.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2023)

Article Biochemistry & Molecular Biology

Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies

Husheng Mei, Hong Wu, Jing Yang, Bin Zhou, Aoli Wang, Chen Hu, Shuang Qi, Zongru Jiang, Fengming Zou, Beilei Wang, Feiyang Liu, Yongfei Chen, Wenchao Wang, Jing Liu, Qingsong Liu

Summary: Enhancer of zeste homolog 2 (EZH2), as an enzymatic subunit of the PRC2 complex, plays a crucial role in tumor development and has gained research interest as a potential therapeutic target. Overexpression or mutations of EZH2 have been associated with tumor cell proliferation in TNBC and DLBCL. Current EZH2 inhibitors have shown promise but resistance can occur due to noncatalytic or transcriptional activity. Researchers have discovered a new irreversible EZH2 inhibitor, IHMT-337, which degrades EZH2 and inhibits cell proliferation in TNBC and DLBCL models in vitro and in vivo. This finding suggests that destroying EZH2 in addition to enzymatic inhibition may be a promising therapeutic strategy.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2023)

Article Chemistry, Medicinal

Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 Diabetes

Yun Wu, Ziping Qi, Beilei Wang, Junjie Wang, Qingwang Liu, Aoli Wang, Chenliang Shi, Bin Zhou, Qianmao Liang, Wenliang Wang, Fengming Zou, Shuang Qi, Zuowei Wang, Li Wang, Wenchao Wang, Jing Liu, Qingsong Liu

Summary: A novel, potent, and selective MST1 inhibitor 19 was discovered, which protected ss cells from inflammatory cytokines in vitro and showed potential in treating diabetes in animal models.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Oncology

Polarized Autologous Macrophages (PAM) Can Be a Tumor Vaccine

Dongqing Wang, Heying Chen, Yi Hu

Summary: Immunotherapy is recognized as a promising strategy for cancer treatment, and reprogramming tumor-associated macrophages from M2 to M1 type is a potential approach. In this study, autologous mouse bone marrow cells were engineered into M1 macrophages and embedded in a gel, which demonstrated the ability to repolarize M2 macrophages to M1 type and activate immune responses, effectively inhibiting tumor recurrence after surgical removal. This suggests that implanting autologous M1 macrophages could be a promising strategy for preventing postoperative tumor recurrence.

ONCOLOGIE (2022)

Review Nanoscience & Nanotechnology

Precision Nanomedicines: Targeting Hot Mitochondria in Cancer Cells

Yi Hu, Rui Dou, Xiaomeng Cai, Lifo Ruan, Jiayu Zhang, Aisha Rouzi, Jun Chen, Zhifang Chai

Summary: Mitochondrion is a crucial organelle in cells and a significant target for antitumor therapy. Differentiating mitochondria in cancer cells from those in normal cells is challenging using conventional mitochondrial targeting strategies, raising concerns about biosafety. Recent studies have identified a relatively high mitochondrial temperature in cancer cells, and this difference can be exploited for specific delivery of therapeutic agents.

ACS APPLIED BIO MATERIALS (2022)

Correction Biochemistry & Molecular Biology

miR-196a provides antioxidative neuroprotection via USP15/Nrf2 regulation in Huntington's disease (vol 209, pg 292, 2023)

Siew Chin Chan, Chih-Wei Tung, Chia-Wei Lin, Yun-Shiuan Tung, Po-Min Wu, Pei-Hsun Cheng, Chuan-Mu Chen, Shang-Hsun Yang

FREE RADICAL BIOLOGY AND MEDICINE (2024)

Article Biochemistry & Molecular Biology

Ribosome-targeting antibiotic control NLRP3-mediated inflammation by inhibiting mitochondrial DNA synthesis

Suyuan Liu, Meiling Tan, Jiangxue Cai, Chenxuan Li, Miaoxin Yang, Xiaoxiao Sun, Bin He

Summary: This study reveals that the antibiotic doxycycline effectively inhibits NLRP3 inflammasome activation by targeting mitochondrial translation and mtDNA synthesis, offering potential for the treatment of NLRP3-related diseases.

FREE RADICAL BIOLOGY AND MEDICINE (2024)

Article Biochemistry & Molecular Biology

Protectin D1 inhibits TLR4 signaling pathway to alleviate non-alcoholic steatohepatitis via upregulating IRAK-M

Hao Liu, Nana Li, Ge Kuang, Xia Gong, Ting Wang, Jun Hu, Hui Du, Minxuan Zhong, Jiashi Guo, Yao Xie, Yang Xiang, Shengwang Wu, Yiling Yuan, Xinru Yin, Jingyuan Wan, Ke Li

Summary: Protectin D1 (PTD1) improves hepatic steatosis, inflammation and fibrosis in a NASH mouse model by inhibiting the activation of TLR4 downstream signaling pathway, possibly through upregulation of IRAK-M expression, suggesting a potential new treatment for NASH.

FREE RADICAL BIOLOGY AND MEDICINE (2024)